Therapeutic potential of megadose vitamin C to reverse organ dysfunction in sepsis and COVID-19

31Citations
Citations of this article
85Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Sepsis induced by bacteria or viruses can result in multiorgan dysfunction, which is a major cause of death in intensive care units. Current treatments are only supportive, and there are no treatments that reverse the pathophysiological effects of sepsis. Vitamin C has antioxidant, anti-inflammatory, anticoagulant and immune modulatory actions, so it is a rational treatment for sepsis. Here, we summarise data that support the use of megadose vitamin C as a treatment for sepsis and COVID-19. Megadose intravenous sodium ascorbate (150 g per 40 kg over 7 h) dramatically improved the clinical state and cardiovascular, pulmonary, hepatic and renal function and decreased body temperature, in a clinically relevant ovine model of Gram-negative bacteria-induced sepsis. In a critically ill COVID-19 patient, intravenous sodium ascorbate (60 g) restored arterial pressure, improved renal function and increased arterial blood oxygen levels. These findings suggest that megadose vitamin C should be trialled as a treatment for sepsis and COVID-19.

Cite

CITATION STYLE

APA

May, C. N., Bellomo, R., & Lankadeva, Y. R. (2021, October 1). Therapeutic potential of megadose vitamin C to reverse organ dysfunction in sepsis and COVID-19. British Journal of Pharmacology. John Wiley and Sons Inc. https://doi.org/10.1111/bph.15579

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free